Navigation Links
Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water
Date:4/12/2013

Fairfax, VA (PRWEB) April 12, 2013

As part of its respected in-depth tracking of bio/pharmaceutical industry trends, PharmSource Information Services, Inc. (PharmSource) has just released its annual report analyzing NDA approvals for 2012 and approval trends for the 2006-2012 period.

Geared to bio/pharma contract manufacturers, as well as to bio/pharmaceutical company procurement executives making sourcing decisions, this proprietary 10-page analysis gives critical insight into evolving contract manufacturing trends and developments, and provides an in-depth data-driven analysis, giving a “who’s who” of contract manufacturing organizations (CMOs) that have received NDA approvals and how they stack up. The report includes data and analysis on several leading indicators including:

  •     Approvals by dosage form, including solid dose, injectable and semisolid/liquid. Data for 2012 is compared against the 2006-2011 trends.
  •     Analysis of the distribution of approvals by sponsor type (small, generic, self-sustaining, global), including data on sponsor types for large molecule vs. small molecule approvals. It includes data on the share of approvals type that were outsourced in 2012 for each sponsor, as well as the 2006-2011 average.
  •     The share of NDA approvals that were outsourced over the period from 2006 to 2012, including a comparison of new molecular entities (NMEs) vs. other NDAs.
  •     Data on the top 19 CMOs that received NDA approvals in 2012, and their comparative approval performance during the 2005-2012 period.
  •     2012 NDA approvals with dose CMOs, including 34 products by sponsor, dosage form, approval type, dose contractors and API contractors.

This report is available by subscription to PharmSource’s Strategic Advantage platform, which includes access to all of PharmSource’s intelligence briefings and in-depth syndicated reports, as well as to its global database of contract manufacturers. It also is available as a stand-alone report. For more information, contact PharmSource directly at +1-703-383-4903 / info[at]pharmsource[dot]com.

About PharmSource
PharmSource brings together buyers and sellers of contract services for the development of drugs, medical devices and diagnostics. A trusted provider of global market and business intelligence since 1996, PharmSource publishes reports and databases, and conducts surveys and analyses related to industry contract service activities and trends.

PharmSource contact information:
+1-703-383-4903 Phone (USA, eastern time-zone)
info(at)pharmsource(dot)com
http://www.pharmsource.com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10625157.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
2. Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software
3. Magnetic actuation enables nanoscale thermal analysis
4. Strategic Analysis of the Collagen Peptide Market in the United States
5. Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Psychemedics Corporation Receives New, Additional FDA Clearances for Hair Analysis Drug Testing
8. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
9. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
10. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
11. New wave of technologies possible after ground-breaking analysis tool developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading provider of educational ... is giving back to cancer research with a month-long promotion supporting the advancement of ... 31, shoppers can use promo code PinkRibbon to get 10 percent off their purchase ...
(Date:10/5/2017)... ... October 05, 2017 , ... ... new applications of its Nanobind DNA/RNA extraction technology . Nanobind is a ... on the surface and that can be used for a wide variety of ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):